faricimab
Selected indexed studies
- Faricimab: First Approval. (Drugs, 2022) [PMID:35474059]
- Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials. (Ophthalmology, 2024) [PMID:38158159]
- Faricimab. (, 2006) [PMID:35230757]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Faricimab: First Approval. (2022) pubmed
- Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials. (2024) pubmed
- Faricimab. (2006) pubmed
- Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. (2022) pubmed
- TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2. (2024) pubmed
- Severe Intraocular Inflammation Following Intravitreal Faricimab. (2024) pubmed
- Faricimab: Transforming the Future of Macular Diseases Treatment - A Comprehensive Review of Clinical Studies. (2023) pubmed
- Efficacy and Safety of Faricimab for Macular Edema due to Retinal Vein Occlusion: 24-Week Results from the BALATON and COMINO Trials. (2024) pubmed
- Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes. (2024) pubmed
- Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. (2022) pubmed